IFNAR2 Antibody

• Research highlights the role of the UL36USP-IFNAR2 interaction in counteracting the type I IFN-mediated signaling pathway. This discovery reveals a novel evasion mechanism employed by HSV-1 to circumvent antiviral innate immunity. PMID: 29997210
• Studies have reported lower serum IFNAR2 levels in multiple sclerosis patients, which are elevated upon treatment with interferon-beta. PMID: 27613121
• This research indicates that the surface expression levels of the common IFN-alpha/beta receptor subunit 2 are significantly higher on plasmacytoid dendritic cells from females compared to males. PMID: 27891600
• A small proportion of pancreatic tumors exhibited strong expression of IFNAR-2c. PMID: 25072284
• The lack of functional IFNAR2 does not appear to be the primary cause of interferon resistance in hepatitis C virus patients undergoing standard interferon therapy. PMID: 26176069
• A research study investigated the influence of two functional polymorphisms, type I interferon receptor 2 gene (IFNAR2)-F8S and interleukin-10 receptor subunit beta gene (IL10RB)-K47E, on chronic hepatitis B virus (HBV) infection. PMID: 23745570
• IFNAR2 overexpression was observed in various histological types of lung cancer and appears to be associated with lung cancers exhibiting aggressive behavior. PMID: 22236545
• This study characterized the Stat2-IFNaR2 interaction and examined its role in IFNalpha signaling. PMID: 11786546
• STAT3 activation by type I interferons depends on specific tyrosines located in the cytoplasmic domain of interferon receptor chain 2c. PMID: 12105218
• Expression and signaling activity of interferon alpha/beta receptors modulate dendritic cell (DC) responsiveness during terminal maturation and differentiation of monocyte-derived DCs. PMID: 12218119
• Subunit 2 of the interferon alpha receptor (IFNaR2) exhibits stronger binding to Stat2 than phosphorylated IFNaR1. PMID: 12220192
• Administration as a complex with sIFNAR-2 may provide a method for enhancing the delivery and effectiveness of type I interferons in Burkitt lymphoma in scid mice. PMID: 14980076
• IFNaR2, a subunit of the type I IFN receptor, undergoes regulated proteolytic cleavage. PMID: 15286706
• Dynamic analysis of the IFNAR2 extracellular domain binding site reveals highly flexible loop segments and a malleable binding surface interacting with the IFN ligand, supported by a more rigid scaffold that stabilizes the binding site conformation. PMID: 15287740
• A dynamic model for the IFN-alpha/receptor complex predicts that IFNAR2 and IFNAR1 are likely anchored in close proximity on the cell surface. Upon IFN binding, the complex adopts a closed form, resulting in activation of intracellular kinases. PMID: 15449939
• IFNAR2 intracellular domain transcriptional modulation depends on the carboxyl-terminal transactivation domain of Stat2. PMID: 15717316
• Interferon-alpha rapidly inhibits MAPK signaling and exhibits an anti-proliferation effect via JAK/STAT signaling in hepatocellular carcinoma cell lines. PMID: 16054712
• Overexpression of IFNAR2 is associated with hepatocellular carcinoma. PMID: 16106266
• Hepatic IFNAR2c mRNA expression appears to correlate inversely with fibrosis stage and age in hepatitis C infection. PMID: 16518956
• Monocyte-derived dendritic cells can modulate their sensitivity to two IFN subtypes through differential regulation of the IFNAR subunits. PMID: 16624932
• The IFNAR2 cytoplasmic domain serves to link STAT4 to the IFNAR as a pre-assembled complex, facilitating cytokine-driven STAT4 activation. PMID: 17095088
• Binding of IFN-alpha8, rather than IFN-alpha2, to IFNAR-2 leads to activation and subsequent antiproliferative activity, despite similar antiviral activity in renal cell carcinoma. PMID: 17572016
• The intensity and distribution of IFNAR-2 may predict the response to therapy with IFN-alpha and IFN-beta in pancreatic cancer. PMID: 17667505
• High IFNAR2 levels are associated with renal cell carcinoma metastasis. PMID: 17697365
• Results indicate that the FNAR2-extracellular domain interacts differentially with two individual IFN-alphas, suggesting a mutual interaction between multiple IFN-alpha subtypes during the competition for receptor binding. PMID: 18027911
• The data suggests that liberation of the IFNaR2-ICD through regulated proteolysis could trigger a novel mechanism for relocating the transcription factor Stat2 to the nucleus. PMID: 18456457
• The Stat3-activating Tyk2 V678F mutant does not up-regulate signaling through the type I interferon receptor, but confers ligand hypersensitivity to a homodimeric receptor. PMID: 18456658
• Findings demonstrate that interferon-alpha/beta receptor (IFNAR)-2 isoforms are significant regulators of responsiveness to both endogenous and systemically administered interferon beta (IFNbeta). PMID: 18971450
• Results suggest that zinc, particularly polaprezinc, enhances the expression of type 1 interferon 2 receptor in U937 cells, thereby inducing the production of the antiviral protein 2'-5'OAS. PMID: 19362011
• Ep-CAM serves as a potentially useful marker for resistance to INFalpha/5-FU therapy, particularly in IFNAR2-positive cases. PMID: 19401692
• The IFNAR2-8SS genotype was associated with HBeAg negative patients; the IFNAR2-8F allele was linked to the risk of high viral loads; the IFNAR2-8FF genotype predisposed to higher MxA gene induction and correlated with sustained IFN response. PMID: 19714778

Show More

Hide All

HGNC: 5433

OMIM: 602376

KEGG: hsa:3455

STRING: 9606.ENSP00000343957

UniGene: Hs.708195